What is Abbiotec?
Abbiotec specializes in the provision of a comprehensive suite of research tools essential for life sciences discovery. Their offerings encompass antibodies, peptides, proteins, and custom synthesis services, catering to researchers and institutions globally. The company's product catalog includes monoclonal and polyclonal antibodies, ELISA kits, and various reagents, supporting critical research areas such as infectious diseases and neurodegenerative conditions like Alzheimer's. By facilitating advancements in proteomics and therapeutic development, Abbiotec empowers scientists in their pursuit of biological understanding and innovation.
How much funding has Abbiotec raised?
Abbiotec has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
What's next for Abbiotec?
With the recent influx of substantial expansion capital, Abbiotec is poised for accelerated growth and enhanced operational capabilities. This strategic investment is expected to fuel further development of their product lines, potentially expanding their reach into new research domains or strengthening their existing market presence. The company's trajectory, marked by significant funding rounds, indicates a strong investor confidence in its business model and its potential to drive innovation within the life sciences research community. Future endeavors will likely focus on scaling production, enhancing R&D efforts, and solidifying its role as a key supplier of critical research reagents.
See full Abbiotec company page
